Imagen Biotech (United Kingdom) a commercial-stage biotechnology assay company focused on analysis of signal transduction pathways and target validation, closed a $40M Series A financing. Participants include SV Life Sciences, Novo Ventures and Fidelity Biosciences.

AcuFocus (Irvine, CA) a commercial-stage medical device company focused on corneal inlays for near-vision loss, closed a $40M Series F financing. Participants include Medtronic, SV Life Sciences, Versant Ventures, Carlyle Group, Accuitive Medical Ventures and Bausch & Lomb.

TransEnterix (San Diego, CA) a clinical-stage medical device company focused on laparoscopic systems for abdominal surgery, closed a $15M Series B financing. Participants include Aisling Capital, Quaker BioVentures, Intersouth Partners, Synergy Life Science Partners and SV Life Sciences.

Catabasis Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on fatty acid conjugated compounds for severe hypertriglyceridemia, diabetes, inflammatory and metabolic diseases, closed a $8M Series A financing bringing total round to $47.6M. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

TopiVert (United Kingdom) a development-stage pharmaceutical company focused on topical medicines for inflammatory diseases of the eye and gut, closed a $12.5M Series A financing. Participants include Imperial Innovations Group and SV Life Sciences.

Affinium Pharmaceuticals (Austin, TX) a clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections, closed a $15M Series B financing. Participants include SV Life Sciences, Genesis Capital Partners, Forward Ventures and Ontario Emerging Technologies Fund. Thanx for your patience as we catch-up.

Entellus Medical (Maple Grove, MN) a commercial-stage medical device company focused on minimally invasive treatments for chronic sinusitis, closed a $35M Series E financing. Participants include Covidien Ventures, SV Life Sciences, Essex Woodlands, Split Rock Partners and Greenspring Associates. Thanx for your patience as we catch-up.

CardioKinetix (Redwood City, CA) a clinical-stage medical device company focused on transcatheter implants for congestive heart failure, closed a $44M Series E financing. Participants include SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Cyterix Pharmacautics (San Francisco, CA) a preclinical-stage small molecule pharmaceutical company focused on oncology,closed a $9.2M Series A financing. Participants include the Column Group and SV Life Sciences.

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

PanOptica (Mount Arlington, NJ) a development-stage biopharma company focused on in licensing IND-stage ophthalmology assets, closed a $30M Series A financing. Participants include SV Life Sciences and Third Rock Ventures.

Arsanis (Austria) a development stage biopharma focused on fully human monoclonal antibodies against severe infectious diseases, closed a $10M A financing. Participants include OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences.

Sutro Biopharma (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on partnering and developing proprietary protein therapeutics that have site directed modifications, closed a $36.5M Series C financing. Participants include Skyline Ventures, Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners.